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OBJECTIVE: This study estimated the total treatment cost of the
orally administrated agent linezolid compared to vancomycin,
administrated through intravenous infusion, in patients with
methicillin resistant Staphylococcus aureus (MRSA) infections in
Sweden. METHODS: Resource consumption for MRSA treat-
ment was divided into four categories; hospital and home care,
pharmaceuticals, administration of intravenous infusion, and
diagnostic tests. Costs were assigned to each resource from ofﬁ-
cial price lists and Statistics Sweden. Total treatment cost was
investigated in a cost-minimization model for a base case where
patients were treated for 14 days and remained at the hospital for
the entire treatment duration. In a sensitivity analysis a range of
parameters were varied and scenarios were investigated where
linezolid patients were able to conclude the treatment at home,
and where all patients were able to conclude treatment at home
(using home care for vancomycin i.v.). Costs were given in 2007
Euro prices. RESULTS: In the base case, the total treatment cost
during 14 days was €9526 for linezolid and €9459 for vancomy-
cin. Pharmaceutical cost was €856 higher for linezolid; however
this cost was offset by lower cost of intravenous administration
and diagnostic tests. The sensitivity analysis showed that for each
day linezolid patients could be treated at home, while vancomy-
cin patients remained at hospital, the linezolid treatment cost
decreased by €558 compared to vancomycin treatment. For each
day both linezolid and vancomycin patients could be treated at
home, the corresponding decrease was €254. CONCLUSION:
When patients remain at the hospital for the entire treatment
duration, the higher pharmaceutical cost of linezolid compared
to vancomycin is almost entirely offset by lower cost of admin-
istration and diagnostic tests. The potential for signiﬁcant cost
reduction lies in enabling patients to conclude their treatment at
home without home care visits. This potential has been shown to
be realized by linezolid.
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Administrative claims data provides tremendous utility in ana-
lyzing speciﬁc real world questions; however, as noted by the
ISPOR Task Force for Retrospective Database Analysis, many
research questions require information beyond the scope of
claims-based databases. The CHIEF Study was designed to
capture complementary survey data to supplement an existing
claims database for evaluating how household cases of inﬂuenza
impact employee productivity. Leveraging existing relationships
with three large employers, the CHIEF Study links monthly
web-based surveys collected during the 2007–2008 inﬂuenza
season with administrative claims from the MarketScan Data-
bases. Three employers, which include a national retail chain, a
transportation company, and a durable goods manufacturing
company, participate in CHIEF. Participant eligibility was based
on having at least one child aged 17 years with employer-
sponsored health insurance that lives in household 4 days per
week. A total of 3686 employees completed the web-based
screening questionnaire; 2295 (62%) of employees were eligible
for study participation. Each month between October 2007 and
May 2008, participants receive an email with an electronic link
to the survey. The baseline surveys include questions about
demographic, health status and health behaviors of all household
members as well as the employee’s workplace characteristics,
absenteeism and presenteeism. The average household includes
2.08 adults and 1.85 children. Employees are approximately
40.77 years old and are predominately full-time workers
(81.91%). Monthly surveys include questions about the presence
of inﬂuenza in the household, the impact of inﬂuenza on
employee productivity and inﬂuenza-related health care use. The
completion rate for the ﬁrst and second monthly surveys was
97.2% (n = 2230) and 96.5% (n = 2213) respectively. Prospec-
tive examination of household illness, absenteeism and presen-
teeism linked with administrative claims data is feasible and
provides an opportunity to understand the impact of disease on
indirect costs. This information can provide more credibility to
future economic analyses and decision making.
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OBJECTIVES: Measles continues to cause considerable morbid-
ity and mortality worldwide. The current measles vaccine is
administered in developing countries through a combination of
routine immunization (RI) at nine months of age plus a second
opportunity (SO)—either another routine injection after one year
of age or via large-scale campaigns. Although these strategies
have proven successful in eliminating measles in the Americas,
measles continues to prove intractable in much of Asia and
Africa due to challenges with vaccine delivery and effectiveness in
current settings. However, several potential measles vaccine tech-
nologies are presently in R&D with the aim to further reduce
measles disease burden compared to the conventional approach
alone. Examples of such technologies include needle-free devices,
DNA vaccines, and/or thermostable vaccines. METHODS: We
developed an age-structured compartmental (dynamic) model of
measles transmission in Nigeria, Uganda and Bihar, parameter-
ized with available demographic, clinical, incidence and sero-
prevalence data. We thus projected future measles cases and
deaths under scenarios of (1) RI alone with current technology;
(2) RI with SO using current technology; (3) RI with new tech-
nologies; and (4) RI and SO with new technologies. We investi-
gated the impact of new technologies under various alternative
assumptions regarding how much they would increase vaccine
coverage and/or vaccine efﬁcacy. A dynamic model was used so
that herd immunity effects can be captured and the estimated
beneﬁts of vaccine innovations thus better estimated. RESULTS:
The effectiveness of RI and SO is enhanced with some of the new
measles vaccine technologies. According to model projections,
new technologies would further reduce the burden of disease in
all three populations, especially at younger ages. CONCLU-
SION: New immunization technologies could help reduce the
measles disease burden in developing countries. However, the
potential cost-effectiveness of using these new technologies and
strategies, including the likelihood of uptake, remains to be
determined.
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